Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 434

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 434
---
 |       |  4,900,000 |   |
| Gain on revaluation of earnout liability         |     |         | - |     |         | - |     |         | (4,880,000 | ) |     |       | (4,880,000 | ) |
| Balance at December 31, 2024                     |     | $       | - |     | $       | - |     | $       |     20,000 |   |     | $     |     20,000 |   |

NOTE 11 – STOCK-BASED COMPENSATION In October 2016, Predecessor’s Board of Directors approved the adoption of an Equity Incentive Plan (“Predecessor EIP”). As amended, the Predecessor EIP permitted the Predecessor to grant awards allowing for the issuance of up to 244,420shares of Predecessor’s common stock. On close of the Merger, outstanding awards issued for the Predecessor EIP were converted to options to purchase a number of shares of the Company’s Common Stock equal to the number of Predecessor shares multiplied by the Merger Exchange Ratio of 0.064452at a price of the Predecessor option strike price divided by the Merger Exchange Ratio. The Predecessor EIP was then cancelled. During the six months ended June 30, 2024, the Company’s Board of Directors granted directors, officers and employees options to purchase up to 2,520shares of Common Stock for exercise prices ranging from $ 704.00per share to $ 9,620.00per share under the 2024 Plan (as defined below). The grants have various vesting conditions, including time-based and performance-based terms. These stock options expire through June 24, 2034. On September 30, 2024 and October 1, 2024, 1,728of these stock options were cancelled due to termination or other reasons. Additionally, on October 1, 2024, the exercise price of the remaining 793outstanding options granted under the 2024 Plan was adjusted to $ 200.00per share, with all other terms of the original grant to remain without adjustment. On October 1, 2024, the Company calculated the total fair value of the consideration for the modification of these stock options, which includes the incremental fair value of the stock options (determined by comparing the fair values immediately prior to and